COST-CONSEQUENCE ANALYSIS COMPARING ROMIPLOSTIM TO RITUXIMAB IN THE TREATMENT OF ADULT PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN GERMANY

被引：0
|
作者：
von Depka, M. [1 ]
Salama, A. [2 ]
Perrin, A. [3 ]
Oelze, I. [3 ]
Chulikavit, M. [3 ]
Kunz, E. [4 ]
Kutikova, L. [4 ]
Thalheimer, M. [5 ]
机构：
[1] Werlhof Inst, Hannover, Germany
[2] Charite Univ Med Berlin, Inst Transfus Med, Berlin, Germany
[3] Analyt LA SER Int Inc, New York, NY USA
[4] Amgen GmbH, Munich, Germany
[5] Univ Klinikum Heidelberg, Heidelberg, Germany
来源：
HAEMATOLOGICA | 2012年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1045
引用
收藏
页码：427 / 427
页数：1
相关论文
共 50 条
  • [31] Extensive cerebral venous sinus thrombosis after romiplostim treatment for immune thrombocytopenia (ITP) despite severe thrombocytopenia
    Ho, P.
    Khan, S.
    Crompton, D.
    Hayes, L.
    INTERNAL MEDICINE JOURNAL, 2015, 45 (06) : 682 - 683
  • [32] Erratum to: Cost Effectiveness of Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in Ireland
    Dawn Lee
    Patrick Thornton
    Alexander Hirst
    Lucie Kutikova
    Robert Deuson
    Nic Brereton
    Applied Health Economics and Health Policy, 2013, 11 (6) : 687 - 687
  • [33] A cost-consequence analysis comparing three cardiac ablation strategies for the treatment of paroxysmal atrial fibrillation
    van de Kar, Mileen
    Dekker, Lukas
    Timmermanns, Ines
    Della Rocca, Domenico
    Chierchia, Gian-Battista
    Da Riis-Vestergaard, Lise
    Uffenorde, Steffen
    Morgan, John
    Chun, Julian
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 826 - 835
  • [34] COST-EFFECTIVENESS OF ROMIPLOSTIM FOR THE TREATMENT OF CHRONIC IMMUNE THROMBOCYTOPENIA IN PORTUGAL
    Augusto, M.
    Gouveia, M.
    Borges, M.
    Campioni, M.
    VALUE IN HEALTH, 2014, 17 (07) : A532 - A532
  • [35] A cost-consequence model comparing valaciclovir and aciclovir for the treatment of acute herpes zoster
    Grant, DM
    Mauskopf, JA
    Austin, R
    Chulay, JD
    Bell, L
    CLINICAL INFECTIOUS DISEASES, 1996, 23 (04) : 108 - 108
  • [36] Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim
    David J. Kuter
    Cynthia Macahilig
    Kelly M. Grotzinger
    Sara A. Poston
    Peter Feng Wang
    Katie L. Dawson
    Melea Ward
    International Journal of Hematology, 2015, 101 : 255 - 263
  • [37] Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim
    Kuter, David J.
    Macahilig, Cynthia
    Grotzinger, Kelly M.
    Poston, Sara A.
    Wang, Peter Feng
    Dawson, Katie L.
    Ward, Melea
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 101 (03) : 255 - 263
  • [38] Reduced corticosteroid use in adult patients with primary immune thrombocytopenia receiving romiplostim
    Michel, Marc
    Boekhorst, Peter A. W. Te
    Janssens, Ann
    Pabinger-Fasching, Ingrid
    Sanz, Miguel A.
    Nie, Kun
    Kreuzbauer, Georg
    HEMATOLOGY, 2011, 16 (05) : 274 - 277
  • [39] Primary immune thrombocytopenia (ITP) treated with romiplostim in routine clinical practice: retrospective study from the United Kingdom ITP Registry
    Doobaree, Indraraj Umesh
    Newland, Adrian
    McDonald, Vickie
    Nandigam, Raghava
    Mensah, Lesley
    Leroy, Sandrine
    Seesaghur, Anouchka
    Patel, Hitan
    Wetten, Sally
    Provan, Drew
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2019, 102 (05) : 416 - 423
  • [40] The treatment for primary immune thrombocytopenia with romiplostim in adult and paediatric patients: use experience at a Spanish university hospital
    Marquinez-Alonso, I.
    Escudero-Vilaplana, V.
    Pernia, S.
    Belendez Bieler, C.
    Fernandez-Llamazares, C. M.
    Sanjurjo-Saez, M.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2014, 39 (04) : 376 - 382
12345